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osting by EAbstract Aim: To assess the level of resting heart rate (RHR) in an outpatient population pre-
senting with stable coronary artery disease (CAD) as well as to measure its association with current
therapeutic management strategies for cardiovascular events.
Materials and methods: A multi-center cross-sectional survey was carried out in Saudi Arabia
and Egypt over a three month period (between January 2007 and April 2007). 2049 patients with
CAD without clinical heart failure (HF) were included in this study through ‘‘cluster sampling’’.
RHR was measured by manual palpitation.
Results: Mean age of CAD patients was 56.7 ± 10.4 and the mean RHR was 78.9 ± 13.9 b/m.
1686 patients (83.1%) were on b-blockers for whom the RHR was 78.5 ± 14.0 b/m (95.5% had
RHRP 60 b/m, which is higher than recommended by the guidelines). 1094 (73.5%) of patients
on b-blockers were on a lower dose, probably to avoid the complications associated with such a
class. Among those not on b-blockers (16.9%), RHR was 80.9 ± 13.0 b/m.AD, coronary artery disease;
lassiﬁcation; HF, heart failure
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226 A.J. Kinsara et al.Moreover, 98 patients (4.8%) were on calcium channel blocker (diltiazem or verapamil) but not
on b-blockers, for whom the RHR was 80.9 ± 12.0 b/m. Finally, 163 patients (8.0%) were on both
b-blockers and the calcium channel blocker, and their RHR was 79.0 ± 14.4 b/m.
Conclusion: Optimal target RHR has not been achieved in a signiﬁcant number of screened
patients. Achievements of such targets are known to decrease mortality and to improve
survival.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Strong evidence suggests a central role of heart rate (HR) in
the pathophysiology of stable angina. An elevation of HR
adversely affects both sides of the myocardial oxygen balance,
myocardial oxygen consumption (MVO2) and decreased
myocardial perfusion (Panza et al., 1992).
Furthermore, a large body of evidence provided by epidemi-
ological studies suggests that high HR is an important cardio-
vascular risk factor, and should be a therapeutic target for
clinicians. The association between HR and cardiovascular dis-
ease has been found not only in patients with chronic ischemic
heart disease, but also among patients with heart failure (Bene-
tos et al., 1999; EUROASPIRE, 1997; Tverdal et al., 2008).
However, little is known about HR level in current medical
practice in the outpatient population with cardiovascular dis-
eases. To date no data is available about RHR in CAD pa-
tients in Saudi Arabia and Egypt. In spite of the evidence,
resting HR is not yet a routine component of cardiovascular
disease risk assessment, or in deciding whether modiﬁcation
of treatment is indicated. This gives a vast potential to further
improve the management in patients with coronary disease or
heart failure; because by not controlling HR there appears to
be a therapeutic opportunity that is being missed.
More recently the BEAUTIFUL study has provided signif-
icant evidence that in patients with CAD and left-ventricular
systolic dysfunction, elevated HR (70 bpm or greater) identi-
ﬁes those at increased risk of cardiovascular outcomes, with
a differential effect on outcomes associated with HR and out-
comes associated with coronary events (Fox et al., 2008).
A studywas conducted inSaudiArabia and inEgypt to specif-
ically evaluate the RHR in CAD population. Stratiﬁed analyses
have been carried out in the two countries and similar results were
found, thus, the two groups were combined together.
2. The primary objective
The primary objective of this study was to assess the level of
RHR in a population presenting with stable CAD. The sec-
ondary objective was to measure the association of RHR with
current therapeutic management strategies for cardiovascular
events. In addition the agreement between the two HR mea-
surements were assessed using the physical palpation and the
electronic device by calculating the correlation coefﬁcient for
the association between these two measurements.
3. Materials and methods
3.1. Study design
An observational cross-sectional, multi-center survey was car-
ried out in the major cities of Saudi Arabia and Egypt. A totalof 2049 patients were selected based on a cluster sampling tech-
nique. Twenty centers were randomly selected by the authors
among tertiary referral hospitals. A random sample of 100 car-
diologists each recruited 20 patients based on a ‘‘stratiﬁed con-
secutive (Quota) sampling’’ technique. These patients were
presented to the clinic. The stratiﬁed aspect of this sampling
procedure was based on the CAD status of the patient. The
‘‘consecutive (Quota)’’ aspect of the sampling was applied to
the ﬁrst 20 patients presenting with stable CAD. Since the
objectives of the study are descriptive in nature, statistical sam-
ple size was not calculated, whereas a convenient sample was
selected for this study.
3.2. Study population
Eligible subjects were male and female outpatients agedP 18
with a history of stable CAD, i.e., with stable angina, history
of revascularization, history of myocardial infarction or of
hospitalization for unstable angina, or having angiographic
evidence of at least 70% narrowing of one of the major coro-
nary arteries.
3.3. Exclusion criteria
Exclusion criteria included patients with clinical heart failure,
i.e. stage II, III, or IV of the NYHA classiﬁcation or patients
with insufﬁcient medical history.
Resting blood pressure and HR: The patients should be at
rest in a sitting position for 5 min. Systolic blood pressure and
diastolic blood pressure were measured by a sphygmomanom-
eter. RHR was measured in three ways; by physical palpation
and counting for 1 min, conﬁrmation of the accuracy of mea-
surements was done either by ECG reading or by an electronic
device (optional). Since the results between the physical palpi-
tation and ECG readings were not statistically different, the
former was taken as reference.
3.4. Data collection
Data were collected for patients, during a single visit, using
structured questionnaires which included a study-speciﬁc iden-
tiﬁcation number and was not related to the patients’ medical
record number. Patient demographics collected included: (age
and sex). Cardiovascular risk factors included smoking,
weight, height, family history of CVD, dyslipidemia, hyperten-
sion, diabetes, and exercise. Moreover, information on history
of cardiovascular events (target organ damage and history of
hospitalization) was also collected and for patients included
for stable angina, average number of angina attacks, short-act-
ing nitrate consumption and grade of pain (according to the
Canadian Cardiology Society Scale). Current cardiovascular
treatments (name of the drug and the total dose/day in mg).
Resting heart rate in patients with ischemic heart disease in Saudi Arabia and Egypt 227b-blocker dose was deﬁned as high dose once the patient took
the optimal recommended dose as per the SPC and was deﬁned
as low for any dose less than indicated.
3.5. Statistical analysis
To take the stratiﬁed sampling procedure adopted in this study
into consideration, all statistical analyses were carried out in
those with stable CAD (without clinical HF symptoms).
Descriptive analyses with means, standard deviations, and
95% conﬁdence intervals around the mean, were calculated
for the HR variable.
Bivariate statistical analyses were carried out to assess the
association between the RHR and each of the different catego-
ries of collected information; demographic variables, cardiovas-
cular risk factors, history of cardiovascular events, NYHA class
(for HF patients), and current cardiovascular treatments.P-val-
ues for these associations were calculated using Student’s t-test
(for associationwith dichotomous variables, such as sex), ANO-
VA (for association with categorical variables with more than
two categories, such as smoking status), andPearson correlation
(for association with continuous variables, such as age).
Predictors for the RHR, including cardiologist information,
were identiﬁed using regression analyses, mainly multiple lin-
ear regression modeling. Interactions between the different risk
factors were checked by including interaction terms in the
regression models.
Datawere entered intoaMicrosoftAccessdatabase structured
speciﬁcally for this study. Data management and analyses were
carried out using the Statistical Analysis Software (SAS, Release
8, SAS Institute Inc., Cary, NC, 1999, USA) (SAS 1999). The
study was approved by the hospital research committee.4. Results
4.1. Patient characteristics
A total of 2049 patients from different centers in the two coun-
tries were included in the study (1035 from Saudi Arabia, and
1014 from Egypt). The general demographics of the patients in
the study are demonstrated in Table 1. The mean age of the
patients was 56.7 (±10.4). Moreover 1403 (70.2%) of the
patients were males.
4.2. Risk factors
Table 1 summarizes the demographics and risk factors for the
included patients as categorized by the HR that was measured
manually. The number of patients in each of HR categories
was 86 (4.2%), 384 (18.9%), 559 (27.6%), 523 (25.8%), and
476 (23.5%) for the <60, 60-70, 71–80, 81–90, and >90,
respectively. There was no signiﬁcant difference in age distri-
bution for the different HR categories (P-value = 0.2). Never-
theless, signiﬁcant association was found between increasing
HR and smoking status, exercise, family history, dyslipidemia,
diabetes and hypertension.
4.3. Drugs used
Table 2 summarizes the drug exposure for the included pa-
tients as categorized by the HR that was measured manually.The drugs that were found to have a signiﬁcant association
with the HR categories were b-blockers. Patients who were
on b-blockers were found to have lower HR, as compared to
those who were not taking these drugs. As expected, dihydro-
pyridine drugs showed a similar association.
4.4. Predictors of high resting heart rate in CAD patients
The predictors considered in this study are summarized in
Table 3, as stratiﬁed by the HRs. There was a signiﬁcant asso-
ciation between HR and stable angina, history of revasculariza-
tion, positive angiography, peripheral arterial disease, stroke,
combined outcomes, and NYHA grade.
In this study the most compelling predictor of increased HR
was smoking (Table 4). Patients with impaired left ventricular
systolic function (NYHA grades I, II and III) were very predic-
tive of high RHR. A higher number of anginal attacks was
associated with higher RHR in this population. There was a po-
sitive impact on RHR in patients who undertook moderate to
intensive exercise or had a history of percutaneous intervention.5. Discussion
The data showed that practice in actuality still differs from
guidelines. All the patients were treated at centers that are
known to practice evidence based medicine, yet only 5% of
the 73% who were on b-blockers achieved the goal stated by
guideline to lower HR under 60 bpm (Task Force 1997).
Shorter appointment time and the use of home HR moni-
tors or the use of home health care services to monitor HR
are practical methods to achieve the target HR set by the
guidelines and overcome the concern on lowering HR.
In patients with stable CAD, most episodes of ambulatory
or exercise-induced myocardial ischemia are preceded by an in-
crease in ischemic attacks, including episodes that occur during
the night. The likelihood of developing ischemia is propor-
tional to the magnitude and duration of the HR increase and
the baseline HR before the increase. The frequency of ambula-
tory ischemic episodes in treated coronary patients is related to
their mean HR; patients with HR >80 b/m experienced ische-
mia almost twice as often as those with HR <70 bpm (An-
drews et al., 1993). These data reinforce the need to measure
and analyze HR in stable coronary patients taking into ac-
count its therapeutic and prognostic role (Diaz et al., 2005;
Beere et al., 1984).
Similar to many epidemiological studies, patients with clas-
sical risk factors, namely current smoking, moderate or inten-
sive exercise, Type I diabetes and NHYA grade who are prone
to cardiovascular disease have higher HR (Palatini et al.,2002).
This supports the facts that the higher RHR, the higher the
morbidity and subsequent mortality (Palatini et al.,1999; Dise-
gni et al., 1995; Jouven et al., 2005).
Patients who have a higher HR, on the other hand, also
demonstrate a higher number of angina attacks, uncontrolled
systolic blood pressure, hospitalization for unstable angina, po-
sitive angiography and even hospitalization for HF (EUROA-
SPIRE, 1997; Perski et al., 1988). This was equally observed in
patients already treated with other HR lowering agents.
Different postulations were thought to explain how elevated
HRmight directly affect cardiovascular risk, including increased
myocardial oxygen demand, energy depletion, accelerated
Table 1 Heart rate among different demographics and risk factors.
Heart rate (manual) P-value
<60 (n= 86, 4.2%) 60–70 (n= 384, 18.9%) 70–80 (n= 559, 27.6%) 80–90 (n= 523, 25.8%) >90 (n= 476, 23.5%)
Age
<49 14 (3.4%) 83 (20.0%) 106 (25.5%) 106 (25.5%) 106 (25.5%) 0.2
49–56 18 (3.2%) 107 (19.4%) 141 (25.5%) 154 (27.9%) 132 (23.9%)
56–65 22 (4.1%) 107 (20.0%) 152 (28.4%) 138 (25.8%) 117 (21.8%)
>65 32 (7.0%) 82 (18.0%) 128 (28.1%) 105 (23.1%) 108 (23.7%)
Gender
Male 66 (4.8%) 286 (20.6%) 400 (28.9%) 347 (25.0%) 287 (20.7%) <0.0001
Female 19 (3.2%) 85 (14.4%) 150 (25.3%) 159 (26.9%) 179 (30.2%)
Smoking
No 45 (4.5%) 192 (19.3%) 260 (26.1%) 247 24.8(%) 253 (25.4%) 0.002
Former 27 (4.9%) 131 (23.5%) 155 (27.8%) 137 (24.6%) 107 (19.2%)
Current 13 (3.2%) 55 (13.6%) 118 (29.1%) 121 (29.9%) 98 (24.2%)
Exercise
None 43 (3.6%) 206 (17.1%) 308 (25.6%) 340 (28.3%) 306 (25.4%) <0.0001
Moderate or intensive 38 (6.0%) 155 (24.3%) 188 (29.4%) 134 (21.0%) 124 (19.4%)
Family history
Yes 25 (3.0%) 148 (18.0%) 204 (24.8%) 233 (28.4%) 212 (25.8%) 0.002
No 49 (5.2%) 187 (19.8%) 281 (29.7%) 220 (23.3%) 208 (22.0%)
Dyslipidemia
Yes 75 (4.8%) 290 (18.4%) 435 (27.6%) 425 (26.9%) 354 (22.4%) 0.005
No 9 (2.3%) 90 (18.4%) 105 (26.7%) 83 (21.1%) 107 (27.2%)
Diabetes
No 43 (4.5%) 224 (23.6%) 251 (26.4%) 224 (23.6%) 208 (21.9%) <0.0001
Type I 7 (3.6%) 27 (13.9%) 36 (18.6%) 49 (25.3%) 75 (38.7%)
Type II 33 (4.1%) 119 (14.7%) 243 (30.1%) 228 (28.2%) 185 (22.9%)
HT
Yes 55 (5.5%) 255 (17.1%) 392 (26.3%) 404 (27.1%) 383 (25.7%) <0.0001
No 28 (5.5%) 125 (24.7%) 157 (31.0%) 108 (21.3%) 88 (17.4%)
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Table 2 Heart rate in relation to different drugs that were used.
Heart rate (manual) P-value
<60 (n= 86, 4.2%) 60–70 (n= 384, 18.9%) 70–80 (n= 559, 27.6%) 80–90 (n= 523, 25.8%) >90 (n= 476, 23.5%)
Beta-blocker
Yes 76 (4.5%) 338 (21.0%) 466 (27.6%) 424 (25.2%) 382 (22.7%) 0.01
No 10 (2.9%) 46 (13.5%) 93 (27.2%) 99 (29.0%) 94 (27.5%)
Low dose 52 (4.8%) 218 (19.9%) 307 (28.1%) 283 (25.9%) 234 (21.4%) 0.8
High dose 22 (5.6%) 85 (21.5%) 103 (26.1%) 95 (24.1%) 90 (22.8%)
Verapamil
Yes 1 (3.0%) 4 (12.1%) 8 (24.2%) 8 (24.2%) 12 (36.4.0%) 0.5
No 85 (4.3%) 380 (19.1%) 551 (27.6%) 515 (25.8%) 464 (23.3%)
Diltiazem
Yes 11 (4.8%) 38 (16.7%) 66 (29.0%) 58 (25.4%) 55 (24.1%) 0.9
No 75 (4.2%) 346 (19.2%) 493 (27.4%) 465 (25.8%) 421 (23.4%)
Dihydropyridine CCB
Yes 18 (3.8%) 74 (15.6%) 115 (24.2%) 128 (27.0%) 140 (29.5%) 0.003
No 68 (4.4%) 310 (20.0%) 444 (28.6%) 395 (25.4%) 336 (21.6%)
ACE inhibitor
Yes 42 (4.4%) 181 (19.1%) 264 (27.8%) 247 (26.0%) 216 (22.7%) 0.96
No 44 (4.1%) 203 (18.8%) 295 (27.4%) 276 (25.6%) 260 (24.1%)
ARB
Yes 21 (3.8%) 87 (15.7%) 134 (24.1%) 156 (28.1%) 157 (28.3%) 0.002
No 65 (4.4%) 297 (20.2%) 425 (28.9%) 367 (24.9%) 319 (21.7%)
Diuretic
Yes 27 (4.2%) 98 (15.2%) 154 (23.9%) 168 (26.1%) 198 (30.7%) <0.0001
No 59 (4.3%) 286 (20.7%) 405 (29.3%) 355 (25.7%) 278 (20.1%)
Antiplatelet
Yes 83 (4.4%) 366 (19.4%) 519 (27.5%) 482 (25.6%) 435 (23.1%) 0.12
No 3 (2.1%) 18 (12.6%) 40 (28.0%) 41 (28.7%) 41 (28.7%)
LA nitrate
Yes 44 (3.4%) 197 (15.3%) 350 (27.2%) 351 (27.2%) 347 (26.9%) <0.0001
No 42 (5.7%) 187 (25.3%) 209 (28.3%) 172 (23.3%) 129 (17.5%)
Lipid lowering
Yes 76 (4.7%) 313 (19.4%) 452 (28.0%) 422 (26.2%) 350 (21.7%) 0.002
No 10 (2.4%) 71 (17.1%) 107 (25.8%) 101 (24.3%) 126 (30.4%)
Vastarel
Yes 41 (4.1%) 181 (18.0%) 285 (28.3%) 273 (27.1%) 228 (22.6%) 0.49
No 45 (4.4%) 203 (19.9%) 274 (26.9%) 250 (24.5%) 248 (24.3%)
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Table 3 Outcomes noted in relation to different baseline heart rate.
Heart rate (manual) P-value
<60 (n= 86, 4.2%) 60–70 (n= 384, 18.9%) 70–80 (n= 559, 27.6%) 80–90 (n= 523, 25.8%) >90 (n= 476, 23.5%)
Stable angina
Yes 63 (4.7%) 233 (17.4%) 372 (27.8%) 366 (27.3%) 306 (22.8%) <0.0001
No 19 (3.7%) 131 (25.8%) 140 (27.6%) 107 (21.1%) 111 (21.9%)
Myocardial infarction
Yes 27 (3.3%) 169 (20.6%) 233 (28.4%) 205 (24.9%) 188 (22.9%) 0.2
No 56 (5.4%) 196 (18.9%) 271 (26.2%) 274 (26.5%) 239 (23.1%)
Hospitalization for unstable angina
Yes 39 (4.4%) 161 (18.0%) 235 (26.3%) 239 (26.7%) 221 (24.7%) 0.06
No 42 (4.7%) 197 (22.2%) 250 (28.2%) 216 (24.4%) 182 (20.5%)
History of revascularization
Yes 43 (5.4%) 183 (22.9%) 220 (27.5%) 208 (26.0%) 147 (18.4%) 0.0007
No 38 (3.8%) 181 (17.9%) 272 (26.9%) 258 (25.5%) 261 25.8(%)
Positive angiography
Yes 50 (5.6%) 187 (21.0%) 245 (27.5%) 250 (28.0%) 160 (17.9%) <0.0001
No 21 (3.2%) 110 (16.6%) 174 (26.2%) 159 (24.0%) 199 (30.0%)
Peripheral arterial disease
Yes 7 (3.2%) 29 (13.1%) 52 (23.5%) 66 (29.9%) 67 (30.3%) 0.01
No 70 (4.4%) 307 (19.4%) 447 (28.3%) 403 (25.5%) 353 (22.3%)
Stroke, TIA
Yes 9 (5.0%) 28 (15.5%) 34 (18.8%) 53 (29.3%) 57 (31.5%) 0.003
No 72 (4.3%) 340 (20.1%) 488 (28.8%) 431 (25.4%) 365 (21.5%)
Outcomes combined
None or 1 31 (3.8%) 141 (17.1%) 238 (28.9%) 197 (23.9%) 217 (26.3%) 0.03
2 or more 55 (4.6%) 243 (20.2%) 321 (26.7%) 326 (27.1%) 259 (21.5%)
Grade
I 40 (6.1%) 157 (24.1%) 195 (29.9%) 150 (23.0%) 110 (16.9%) <0.0001
II 19 (3.2%) 106 (17.8%) 166 (27.8%) 178 (29.8%) 128 (21.4%)
III 9 (3.3%) 33 (12.2%) 63 (23.3%) 68 (25.1%) 98 (36.2%)
IV 0 (0.0%) 10 (20.8%) 9 (18.8%) 8 (16.7%) 21 (43.8%)
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Table 4 The predictors of increased heart rate, calculated by multiple linear regression.
Regression model
Coeﬃcient 95% CI P-value
Variables that show signiﬁcance
Current smoker 2.31 (0.80, 3.83) 0.003
Moderate or intensive exercise 2.12 (3.39, 0.85) 0.001
Type I diabetes 2.35 (0.29, 4.41) 0.03
NHYA grade II 1.47 (0.15, 2.81) 0.03
NHYA grade III 2.81 (0.93, 4.69) 0.003
NHYA grade IV 3.74 (0.29, 7.77) 0.07
Age 0.16 (0.22, 0.10) <0.0001
Number of angina attacks 0.31 (0.14, 0.48) 0.0004
Systolic blood pressure 0.10 (0.06, 0.14) <0.0001
Diastolic blood pressure 0.15 (0.09, 0.21) <0.0001
Gender 1.55 (0.16, 2.94) 0.03
Hospitalization for unstable angina 1.50 (0.21, 2.78) 0.02
Positive angiography 2.20 (3.48, 0.91) 0.0008
Hospitalization for heart failure 5.81 (3.62, 8.00) <0.0001
Resting heart rate in patients with ischemic heart disease in Saudi Arabia and Egypt 231atherosclerosis, or increased risk of plaque rupture (Giannog-
lou et al., 2008; Heidland et al., 2001). This study and similar
studies highlighted the need to have a group of drugs that con-
trol HR and without the fear of side effect of AV nodal block-
ing agent (Fox et al., 2008; DiFrancesco et al., 2005).
This study shows us that although 83% of the patients were
taking b-blockers 95% had a RHR above 60 bpm. One of the
main reasons for this result was 73% of the patients were tak-
ing a low dose of the b-blocker. There are several reasons be-
hind the suboptimal dosage used for b-blockers, which include
the frequency of side effects like bradycardia and sexual dys-
function, while at the same time for many doctors HR does
not inﬂuence decision making.
The results highlight the importance of HR control in the
management of stable coronary patients. Deﬁnitely better
awareness of the implications of high RHR for all physicians
treating CADpatients might help prevent future cardiovascular
events; this can be further enforced through national guidelines.
6. Conclusion
This epidemiological data has shown that RHR is not achieved
in a good number of patients and that high RHR is associated
with multiple morbidity outcomes.
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